Clinical Trial Update: Phase 3 Study of Walter Reed (WR) 279,396 and Paromomycin Alone for the Treatment of Cutaneous Leishmaniasis in Panama [Phase 3]

View source ↗

Summary

Phase 3 study evaluating Walter Reed (WR) 279,396 and paromomycin alone for cutaneous leishmaniasis completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Leishmaniasis

Drugs mentioned

• Paromomycin (paromomycin)
• Walter Reed (WR) 279,396

Snippet

Sponsor: U.S. Army Medical Research and Development Command | Conditions: Cutaneous Leishmaniasis | Phase 3 | Status: COMPLETED | Results posted: 2017-08-23